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Myotonic dystrophy 1 (MD1) is caused by a CTG expansion in the 30-unstranslated region of the myo-
tonic dystrophy protein kinase (DMPK) gene. MD1 patients frequently present insulin resistance and
increased visceral adiposity. We examined whether DMPK deﬁciency is a genetic risk factor for high-
fat diet-induced adiposity and insulin resistance using the DMPK knockout mouse model. We found
that high-fat fed DMPK knockout mice had signiﬁcantly increased body weights, hypertrophic adi-
pocytes and whole-body insulin resistance compared with wild-type mice. This nutrient–genome
interaction should be considered by physicians given the cardiometabolic risks and sedentary life-
style associated with MD1 patients.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Myotonic dystrophy 1 (MD1), an autosomal dominant neuro-
muscular disorder, is the most common form of adult muscular
dystrophy [1]. The MD1mutation has been identiﬁed as the expan-
sion of an unstable CTG-repeat in the 30-untranslated region of a
gene encoding the serine/threonine protein kinase myotonic dys-
trophy protein kinase (DMPK) [2–5].
Studies in mice have indicated that several mechanisms may
simultaneously contribute to the wide spectrum of symptoms ob-
served in MD1 [6,7]. One of the mechanisms proposed is that the
repeat expansion affects the level of DMPK expression in cis by
altering its transcription or by retaining DMPK transcripts in the
cell nucleus. This results in a decrease in the amount of DMPK pro-
tein expression, or haploinsufﬁciency. Results from DMPK knock-
out mice – which develop mild myopathy, cardiac abnormalities
and metabolic alterations – give experimental support to this
mechanism [8–11].
Insulin resistance, which is a major factor in the development of
type 2 diabetes [12], is a metabolic feature in MD1 patients, who
frequently exhibit normal basal insulin levels but excessive insulinchemical Societies. Published by E
).release after a glucose load [13,14]. Whole-body glucose disposal in
MD1 patients is reduced by 1525% following insulin infusion [15]
and experiments with forearm muscle indicate a 70% decrease in
insulin sensitivity in skeletal muscle [16]. In MD1 patients, fat mass
is signiﬁcantly increased and lean body mass is decreased [17–20].
Computerized tomography (CT) scanning at the umbilical level
revealed increased visceral fat area in MD1 patients compared with
healthy controls. Visceral fat area in MD1 patients correlated
positively with plasma glucose levels in the glucose tolerance
test, and with serum total cholesterol and triglycerides [21]. More-
over, comparison between MD1 patients with long and short CTG
repeat expansions did not reveal signiﬁcant differences in body
mass index or body fat mass [22], indicating that their fat accumu-
lation is not exclusively related with the degree of toxicity of the
long repeats.
Here we explored whether DMPK deﬁciency is a genetic risk
factor for adiposity and systemic insulin resistance, by examining
the metabolic phenotype of DMPK KO mice after a 6-week high-
fat diet (HFD). We found that under the dietary stress of a high-
fat regime, DMPK knockout mice developed more overweight
and whole-body insulin resistance than wild type mice. These data
indicate that in MD1 patients, DMPK underexpression may interact
with environmental factors to induce a phenotype of prediabetes
and increased adiposity.lsevier B.V. All rights reserved.
Fig. 1. (A) Changes in body weight of DMPK knockout (KO) and wild type (WT)
mice (n = 10 animals/group) during a 6-week high-fat diet. The box shows body
weight increases from mice fed a standard (St) or high-fat (HF) diet for 6 weeks. (B)
Food intake of DMPK/ and wild type mice during the 6-week high fat diet. (C)
Home cage activity was automatically recorded by video tracking in specially
designed home cages for automated recordings. Ambulation (horizontal displace-
ments) and small movements (grooming behaviour, small rearings and stereotyped
movements) were measured (n = 8 animals/group). Data are means ± S.E.M.
*P < 0.05, **P < 0.01 versus the corresponding wild-type value.
2122 E. Llagostera et al. / FEBS Letters 583 (2009) 2121–21252. Materials and methods
2.1. Mouse experiments
All animal studies were performed in accordance with the
guidelines and under approval of the Institutional Review Commit-
tee for the Animal Care and Use of the University of Barcelona. The
dmpk/+ heterozygous mice on 129SV background were generated
by Reddy et al. [8]. Mice were backcrossed at least 9 times main-
taining them as congenic in the colony.
The normal diet contained 4% fat by weight (11% of calories from
fat) (Teklad Global 14% Protein Rodent Maintenance Diet, Harlan
Teklad, Madison, WI), while the high-fat diet had 34.9% fat by
weight (60% of calories from fat) (D12492, Research Diets; New
Brunswick, NJ). For diet treatments, 2-month old male mice were
individually fed a normal or a fat-adjusted diet for 6 weeks (two
cohorts of DMPK knockout and wild-type mice, each containing at
least 10 animals/genotype/diet). Weight and food intake were
measured daily.
2.2. Home cage activity
Home cage activity was automatically recorded by video track-
ing in specially designed individual cages for automated recordings
(Med Associates, Inc.). Mice were monitored by an infra-red-sensi-
tive camera mounted above the cages, which was connected to a
computer running the video tracking software programmed to
measure two types of activity: ambulation (horizontal displace-
ments) and small movements (grooming behaviour, small rearings
and stereotyped movements). The session lasted 24 h, starting be-
tween 2:00 and 3:00 pm. Lights were automatically turned off at
8:00 pm and on at 8:00 am.
2.3. Metabolic measurements
Blood glucose levels in whole venous blood were measured
using an automatic glucose monitor (AccuChek, Roche Diagnos-
tics One Touch Basic, Lifescan). Plasma insulin levels were mea-
sured by ELISA, using rat insulin as a standard (Crystal Chem).
Insulin tolerance tests (ITT) were performed on animals that had
been fasted overnight and injected with 0.75 unit/kg body weight
of human regular insulin (Lilly). LINCO Research Mouse Adiponec-
tin ELISA Kit (Cat.#EZMADP-60K) was used to determine adipo-
nectin levels in plasma samples from fed male mice. Liver lipid
was extracted as described [23]. Free fatty acids, cholesterol
and triglyceride levels were measured using kits from Wako
Chemicals.
2.4. Histological studies
Adipose tissues were ﬁxed in 95% ethanol, embedded in parafﬁn
and cut into 8 lm sections. Hematoxylin and eosin staining was
performed following standard protocols. Image areas were deter-
mined using the MacBiophotonics Image J software. Average adi-
pocyte size was determined in 15 randomly selected ﬁelds per
animal, from a total of 5 animals per condition. A relative estima-
tion of the total number of cells was obtained as cell number/
mm2  total tissue weight (mg).
Pancreas were ﬁxed in phosphate buffered paraformaldehyde
(4% w/v), dehydrated, embedded in parafﬁn and cut into 5 lm sec-
tions. Insulin immunostaining was performed using a peroxidase
indirect labeling technique, as previously reported [24]. Islet area
was determined by manually circumscribing the outline of all the
islets in a section from a total of three tissue sections per animal
(n = 5 animals/group).2.5. Statistical analysis
Data are presented as mean ± S.E. Statistical analysis was per-
formed using a two-tailed unpaired t-test. Values of P < 0.05 were
considered as statistically signiﬁcant.
3. Results
Body weight of DMPK knockout (KO) and wild type (WT) mice
fed normal chow or high-fat (HF) diet was monitored. Absolute
body weight and body weight increase were already signiﬁcantly
higher after 2 weeks of HF diet in the DMPK KO mice and the dif-
ference persisted over time (Fig. 1A). This difference was not due to
increased food intake, as both KO and WT mice consumed compa-
rable amounts of food during this period (Fig. 1B). Body weights of
KO on a normal diet were similar to those of control mice (Fig. 1A).
Overweight in KO compared to WT mice could not be attributed to
mobility impairment as assessed in home cage activity studies
(Fig. 1C). Therefore, the increased weight gain of KO compared to
WT mice, despite equal energy intake and physical activity, impli-
cates DMPK in the regulation of energy balance.
No differences in the weight of liver, heart, skeletal muscle,
brown adipose tissue, or pancreas were observed between WT
and KO mice on high fat diet (Fig. 2A). However, the weights of
epididymal and subcutaneous white adipose tissues (WAT) were
Fig. 2. (A) Weight of various tissues (from left to right: liver, heart, gastrocnemius, brown adipose tissue and pancreas) from DMPK knockout (KO) and wild type (WT) mice
(n = 10 animals/group) at the end of the 6-week high-fat diet. (B) Weight of subcutaneous (sc) and epididymal (e) white adipose tissue (WAT) from KO andWTmice at the end
of the 6-week high fat diet (n = 10 animals/group). (C) Representative hematoxylin and eosin staining of epididymal WAT from KO and WT mice at the end of the 6-week
high-fat diet (n = 5 animals/group). Scale bar, 100 lm. (D) Distribution of adipocyte size in epididymal WAT from KO andWTmice at the end of the 6-week high fat diet (n = 5
animals/group). (E) Estimation of adipocyte number in epididymal WAT from KO and WT mice at the end of the 6-week high-fat diet (n = 5 animals/group). Data are
means ± S.E.M. *P < 0.05, **P < 0.01 versus the corresponding wild-type value.
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similar in wild type and DMPK KO mice fed a normal diet (data not
shown). A signiﬁcant increase in the size of adipocytes in epididy-
mal WAT was observed in the KOmice fed a HF diet compared with
WT controls (45 ± 10% increase, n = 5 per condition analyzed,
P = 0.014) (Fig. 2C and D); this effect was not accompanied by a
signiﬁcant difference in cell number (Fig. 2E). We did not detect
signiﬁcant differences in the expression of PPARc, PGC-1a or
adiponectin in WAT from KO compared with WT mice after the
HF diet (data not shown).
Table 1 summarizes metabolic parameters of KO and WT
mice on normal and HF diet. While the insulin plasma levels
remained similar in both groups after the HF diet, fast glycaemiaTable 1
Metabolic parameters from mice fed a normal or high-fat diet for 6 weeks. All data are m
Normal diet
WT K
Glycaemia (mg/dL) (fed) 114.2 ± 4.26 10
Glycaemia (mg/dL) (fast) 64.00 ± 2.58 65
Insulinemia (lg/mL) (fed) N.D N
Insulinemia (lg/mL) (fast N.D N
Plasma adiponectin (ng/mL) 11.55 ± 0.81 11
Plasma TG (g/L) N.D N
Plasma NEFA (mM) N.D N
Hepatic TAG (mg/g) 21.30 ± 1.16 23
Hepatic CHOL (mg/g) 1.36 ± 0.08 1.
* P < 0.05 (n = 10 animals/group).in HF-fed KO mice was signiﬁcantly higher than that of WT mice
(P = 0.008). Plasma adiponectin was comparable between WT and
DMPK KO mice. Similar plasma lipid levels were found in KO and
WT mice fed high fat diets. Triglyceride and cholesterol accumula-
tion in liver was similar in KO and WT mice after the HF diet,
indicating that DMPK did not inﬂuence hepatic lipid storage.
We examined the effect of dmpk ablation on whole-body insulin
sensitivity after 6 weeks on HF diet. Insulin tolerance tests (ITT)
revealed no differences in the blood glucose levels between KO
and WT mice on normal chow (Fig. 3A). Both groups showed a
decreased response to exogenous insulin after the HF diet inter-
vention, reﬂecting increased insulin resistance at these pharmaco-
logical levels of hormone. However, DMPK KO mice developed aeans ± S.E.M.
High-fat diet
O WT KO
9.2 ± 3.86 122.5 ± 3.78 119.4 ± 3.91
.07 ± 2.16 74.43 ± 5.06 96.29 ± 4.88*
.D 1.36 ± 0.14 1.06 ± 0.10
.D 0.20 ± 0.05 0.12 ± 0.02
.47 ± 1.04 13.19 ± 0.79 13.29 ± 0.72
.D 0.53 ± 0.04 0.59 ± 0.05
.D 1.11 ± 0.12 1.21 ± 0.13
.96 ± 3.04 86.94 ± 22.91 68.33 ± 12.00
34 ± 0.08 5.05 ± 0.59 3.89 ± 0.22
Fig. 3. (A) Insulin tolerance test. Blood glucose levels in KO and WT mice (n = 10/
group) fed a normal or high-fat diet for 6 weeks were determined at the indicated
times after intraperitoneal injection with a bolus of insulin. (B) Peroxidase
immunostaining of pancreatic sections with insulin antibodies. Representative
sections of pancreas from KO and WT mice at the end of the 6-week high fat-diet
are shown (n = 5 animals/group). (C) The number of islets containing insulin
positive cells per pancreas area (mm2) was measured in pancreas sections from KO
and WT mice at the end of the 6-week high fat-diet, as indicated in Methods (n = 5
animals/group). All data are means ± S.E.M. *P < 0.05, **P < 0.01 versus the corre-
sponding wild-type value.
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(Fig. 3A).
In order to establish whether insulin resistance in the DMPK KO
mice affected the insulin-producing cells, we immunostained pan-
creatic tissue sections to speciﬁcally analyze insulin expression.
(Fig. 3B and C). No differences were observed in the measurement
of pancreatic beta cell mass in the KO mice compared with the WT
mice after the high fat diet.
4. Discussion
We have recently provided in vivo and in vitro evidence for the
role of DMPK in the regulation of insulin action and glucose
homeostasis [25]. Those ﬁndings indicated that reduced DMPK
expression may directly inﬂuence the onset of insulin-resistance
in MD1 patients and suggested that DMPK could represent a sus-
ceptibility gene to type 2-diabetes. Here we demonstrate that a
high-fat (HF) diet leads to adverse metabolic outcomes (i.e. sys-
temic insulin resistance and visceral fat accumulation) in a genetic
context of DMPK deﬁciency.
Our data show that a HF diet aggravates the already alteredmet-
abolic phenotype of DMPK KO mice fed a normal diet. Indeed,compared with the WT control mice, the DMPK KO mice on the
HF diet exhibited increased bodyweight and fatmass. Interestingly,
when fed a normal diet, the KO mice showed no alterations in the
insulin tolerance tests. However, after the HF diet, systemic insulin
sensitivity was signiﬁcantly lower in KO compared with WT mice.
After 6 weeks on a HF diet, KO mice also showed increased white
adipose tissue mass compared with WTs, in the absence of any
detectable change in pancreas structure, adipocyte marker expres-
sion, or adiponectin secretion. The increase in adipose tissue mass
correlated with adipocyte hypertrophy. After the HF regime, DMPK
KO mice showed a slight but signiﬁcant increase in fast glycaemia
but did not show differences in fed blood glucose, plasma insulin
or plasma lipid levels compared with WT mice.
It is well established that accumulation of lipids in non-adipose
cells leads to cell dysfunction, i.e. insulin resistance in skeletal mus-
cle [26] and impaired insulin secretion and apoptosis in pancreatic
b-cells [27,28]. The ﬁnding that serum lipid levels were not elevated
in DMPK KOmice as compared withWTmice, and that both groups
had similar triglyceride content in liver, indicates that the increase
in lipid storage in adipose tissue in DMPK KO mice may have pro-
tected these mice from systemic lipotoxicity and further impair-
ment of glucose homeostasis and metabolic alterations.
In MD1 patients, the primary muscular disease usually leads to
inactivity and sedentary lifestyles, which in turn may contribute to
overweight and obesity, as well as cardiometabolic risk. Moreover,
overweight and obesity often lead to prediabetes which confers a
6-fold increased risk of diabetes compared with normal glucose
tolerance [29]. In this context, our data showing that DMPK KO
mice present signiﬁcantly higher metabolic risks under a HF diet
than the WT mice (i.e. insulin resistance and visceral adiposity),
point to a nutrient–genome interaction which physicians should
take into account for early prevention and management of co-mor-
bid cardiometabolic risks in Myotonic Dystrophy 1 patients.Acknowledgements
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